Overview

Phase II Trial to Correlate Radiographic Response Induced By Gefitinib With Mutations in the Protein-Tyrosine Kinase Domain of the EGF Receptor Gene

Status:
Completed

Trial end date:
2010-09-01

Target enrollment:

Participant gender:

Summary

The purpose of this research study is to: - see if gefitinib pills can shrink Stage 1 or 2 non-small cell lung cancers before surgery - see if your non-small cell lung cancer has a mutation in a certain part of the EGFR gene - see if patients whose tumor does shrink with gefitinib treatment are more likely to have a mutation in a certain part of the EGFR gene - see if the pattern of protein expression in the blood is related to the tumor's sensitivity or resistance to gefitinib treatment. - see if expression of certain genes in the tumor are related to the tumor's sensitivity or resistance to gefitinib treatment.

Phase:

Phase 2

Details

Lead Sponsor:

Memorial Sloan Kettering Cancer Center

Treatments:

Gefitinib